Frontotemporal dementia with the V337M MAPT mutation

Neurology

Volumn 88, Issue 8, 2017, Pages 758-766

  Spina, Salvatore ^a   Schonhaut, Daniel R ^a   Boeve, Bradley F ^b   Seeley, William W ^a   Ossenkoppele, Rik ^a,c,d   O'Neil, James P ^e   Lazaris, Andreas ^a   Rosen, Howard J ^a   Boxer, Adam L ^a   Perry, David C ^a   Miller, Bruce L ^a   Dickson, Dennis W ^f   Parisi, Joseph E ^b   Jagust, William J ^c,e   Murray, Melissa E ^e   Rabinovici, Gil D ^a,c,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLORTAUCIPIR F 18; METHIONINE; TAU PROTEIN; VALINE; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE; MAPT PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT;

ADULT; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD BIOCHEMISTRY; BRAIN; BRAIN ATROPHY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; FAMILY HISTORY; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENETIC ASSOCIATION; GLIA; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; MALE; MIDDLE AGED; MOTHER; NERVE CELL; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIRED HELICAL FILAMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TAUOPATHY; AGED; CASE REPORT; DIAGNOSTIC IMAGING; FATALITY; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

AGED; BRAIN; CARBOLINES; FATAL OUTCOME; FEMALE; FRONTOTEMPORAL DEMENTIA; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TAU PROTEINS;

EID: 85013459749     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003636     Document Type: Article

References (34)

1. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002;58: 1615-1621.
2. Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry 2013;25:130-137.
3. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456-2477.
4. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006-1014.
5. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-705.
6. Clark LN, Poorkaj P, Wszolek Z, et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci USA 1998;95: 13103-13107.
7. Poorkaj P, Bird TD, Wijsman E, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998;43:815-825.
8. SpillantiniMG, Murrell JR, Goedert M, FarlowMR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA 1998;95:7737-7741.
9. van Swieten J, Spillantini MG. Hereditary frontotemporal dementia caused by tau gene mutations. Brain Pathol 2007;17:63-73.
10. Bird TD, Wijsman EM, Nochlin D, et al. Chromosome 17 and hereditary dementia: linkage studies in three non- Alzheimer families and kindreds with late-onset FAD. Neurology 1997;48:949-954.
11. Sumi SM, Bird TD, Nochlin D, Raskind MA. Familial presenile dementia with psychosis associated with cortical neurofibrillary tangles and degeneration of the amygdala. Neurology 1992;42:120-127.
12. Spillantini MG, Crowther RA, Goedert M. Comparison of the neurofibrillary pathology in Alzheimer's disease and familial presenile dementia with tangles. Acta Neuropathol 1996;92:42-48.
13. Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013;9:666-676.
14. Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015;78:787-800.
15. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013;34:457-468.
16. Ossenkoppele R, Schonhaut DR, Baker SL, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol 2015;77:338-342.
17. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016;79:110-119.
18. Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun 2016;4:58.
19. Smith R, Puschmann A, Scholl M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 2016;139:2372-2379.
20. Josephs KA, Whitwell JL, Tacik P, et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 2016;132:931-933.
21. Yokoyama JS, Sturm VE, Bonham LW, et al. Variation in longevity gene KLOTHO is associated with greater cortical volumes. Ann Clin Transl Neurol 2015;2:215-230.
22. Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013;136:844-858.
23. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11-22.
24. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 2000;97:11050-11055.
25. Ossenkoppele R, Schonhaut DR, Scholl M, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 2016;139:1551-1567.
26. Baker SL, Lockhart SN, Price JC, et al. Reference tissuebased kinetic evaluation of 18F-AV-1451 in aging and dementia. J Nucl Med. Epub 2016 Sep 1.
27. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-413.
28. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
29. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1-13.
30. Murray ME, Cannon A, Graff-Radford NR, et al. Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol 2014;128:411-421.
31. Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011;122:111-113.
32. Lin WL, Castanedes-Casey M, Dickson DW. Transactivation response DNA-binding protein 43 microvasculopathy in frontotemporal degeneration and familial Lewy body disease. J Neuropathol Exp Neurol 2009;68:1167-1176.
33. Spina S, Farlow MR, Unverzagt FW, et al. The tauopathy associated with mutation 13 in intron 10 of tau: characterization of the MSTD family. Brain 2008;131:72-89.
34. Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M. Frontotemporal dementia caused by MAPT mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 2015;41:24-46.